Associations of Carotid Plaque Characteristics With Brain Perfusion and Cognitive Function in Patients Undergoing CEA
NCT ID: NCT04955015
Last Updated: 2021-07-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2019-09-01
2023-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Prognosis of Surgical Intervention in Patients With Carotid Artery Stenosis
NCT06222983
Change of Hemodynamics and Cerebral Functions After Carotid Artery Revascularization
NCT05539781
Early Warning and Optimization Strategy in Carotid Endarterectomy
NCT01210937
Combined Coronary and Cerebral Angiography and Intervention for Coronary and Cerebrovascular Atherosclerosis
NCT02315924
Ultrasound Evaluation of Carotid Artery Atherosclerotic Plaques and Recanalization
NCT03786666
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
At present, the main treatment methods of carotid artery stenosis are: carotid endarterectomy (CEA) and carotid angioplasty with stenting (CAS). Large scale multicenter prospective randomized trials and meta-analysis have established CEA as the gold standard for the treatment of carotid arerosclerotic stenosis.
Studies have shown that the ipsilateral cerebral perfusion is continuously decreased due to carotid artery stenosis, and CEA operation can relieve the vascular stenosis and improve the cerebral perfusion. However, the relationship between cerebral perfusion improvement after CEA and the quantitative characteristics of vulnerable plaque is still lack of sufficient evidence. Vascular cognitive impairment is closely related to the progress of carotid stenosis. The main mechanisms are microemboli formation, white matter injury and central nervous function decline caused by long-term chronic hypoperfusion. The formation and continuous hypoperfusion of microemboli further increase the burden of white matter disease. Studies have shown that the visual spatial executive ability, naming ability, attention ability and abstract profile ability of patients after CEA are significantly improved. However, there is still insufficient evidence about the relationship between the MRI features of vulnerable carotid plaques and the improvement of cognitive function after CEA.
We hope to achieve the following goals: 1) to explore the associations between carotid vulnerable plaque characteristics and cerebral perfusion in patients undergoing CEA; 2) to explore the associations between the characteristics of vulnerable carotid plaques and cognitive function in patients undergoing CEA.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
patients
patients with caotid atherosclerosis refering to carotid endarterectomy
carotid endarterectomy
patients with carotid atherosclerosis refering to CEA
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
carotid endarterectomy
patients with carotid atherosclerosis refering to CEA
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The patients with symptomatic (\>50%) or asymptomatic carotid stenosis (\> 70%) measured by computed tomography angiography (CTA) or B-mode ultrasonography
3. CEA operation will be performed in our hospital.
Exclusion Criteria
2. Diseases (AF, valve diseases, etc.) that may cause cardiac thrombosis;
3. Contraindications of MR examination (vascular stent implantation, pacemaker, metal or magnetic plants in vivo, claustrophobia, etc.) were found;
4. Contraindications of contrast agents: such as renal failure, iodine or gadolinium contrast agent allergy;
5. Having heart or respiratory failure;
6. Serious consciousness disorder (coma, etc.);
7. Brain tumor;
8. Acute cerebral hemorrhage;
9. Pregnant women or planned pregnancies in the past 2 years;
10. Who does not agree to sign the informed consent.
30 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University Third Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Huishu Yuan, Dr.
Role: STUDY_CHAIR
Peking University Third Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University Third Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M2019292
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.